Medipost Co., Ltd

Samsung Life Public Welfare Foundation

Encell Co., Ltd.

Hong Bae Jeon

Yoon-Sun Yang

Won Il Oh

Mi Yeon Lee

Sun Jae Kwon

Mee Hyun Jung

Sang Young Jeong

Jong Wook Chang

Soo Jin Choi

Wonil Oh

Miyeon Kim

Ju-Yeon Kim

Hoon Lim

Hye Jin Jin

Shin Ji Oh

Sang Eon Park

Yoon Sun Yang

Jang Young Lee

The present invention relates to a pharmaceutical composition, for preventing or treating Charcot-Marie-Tooth disorder, comprising mesenchymal stem cells or insulin secreted by mesenchymal stem cells.

Pharmaceutical composition, for preventing or treating Charcot-Marie-Tooth disorder, comprising mesenchymal stem cells or insulin secreted by mesenchymal stem cells

Disclosed is a method for culturing mesenchymal stem cells, comprising culturing mesenchymal stem cells in a medium containing calcium in a concentration of from 2.1 to 3.8 mM and magnesium in a concentration of from 1.0 to 3.0 mM under a hypoxic condition of 2 to 5% oxygen. The culturing method can increase the population of mesenchymal stem cells even with a small number of passages by improving mesenchymal stem cells in proliferative capacity and viability. In addition, the mesenchymal stem cells prepared by the culturing method are effectively used to treat or improve a pulmonary disease.

Method for culturing mesenchymal stem cells

A pharmaceutical composition for the prevention or treatment of a pulmonary disorder is provided. The composition contains mesenchymal stem cells showing improved proliferation and differentiation capacity which are characterized by the expression or non-expression of one or more particular cell markers. Also, provided is a method for obtaining mesenchymal stem cells showing improved proliferation and differentiation capacity based on the expression or non-expression of such cell markers. The mesenchymal stem cells having improved proliferation and differentiation capacity can be easily obtained from mesenchymal stem cells of various origins based on the expression or non-expression of CD26, CD49f, CD146 and EGFR. The mesenchymal stem cells thus obtained can be effectively used for the prevention or treatment of a pulmonary disorder such as, for example, pulmonary emphysema.

Pharmaceutical composition for the prevention or treatment of a pulmonary disorder comprising mesenchymal stem cells having improved proliferation and differentiation capacity

Disclosed is a method for culturing mesenchymal stem cells, comprising culturing mesenchymal stem cells in a medium containing calcium in a concentration of from 2.1 to 3.8 mM and magnesium in a concentration of from 1.0 to 3.0 mM under a hypoxic condition of 2 to 5% oxygen. The culturing method can increase the population of mesenchymal stem cells even with a small number of passages by improving mesenchymal stem cells in proliferative capacity and viability. In addition, the mesenchymal stem cells prepared by the culturing method are effectively used not only as a safe cell therapeutic agent due to their lacking immunogenicity, but also as a cartilage regenerating medicine owing to their excellent secretion of cytokines.

Thrombospondin 1 (TSP-1), TSP-2, interleukin 17B receptor (IL-17BR) and heparin-binding epidermal growth factor-like growth factor (HB-EGF) associated with stem cell activity and use thereof.

Treating cartilage defect with UCB-MSC expressing TSP-2

Method of selecting stem cells having high chondrogenic differentiation capability

Growing community of inventors

Seoul, South Korea

Hong Bae Jeon